Du Wei, Chen Chen, Liu YingYing, Quan Huiyi, Xu Ming, Liu JingJing, Song Ping, Fang ZhiQiang, Yue ZhenSheng, Xu Hao, Ling YuWei, Duan JuanLi, He Fei, Wang Lin
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Cell Rep Med. 2025 Apr 15;6(4):102033. doi: 10.1016/j.xcrm.2025.102033. Epub 2025 Mar 21.
Drug-induced liver injury (DILI) involves multifaceted pathogenesis, necessitating effective therapeutic strategies. Wnt2, secreted by liver sinusoidal endothelial cell (LSEC), activates the Wnt/β-catenin signaling pathway to promote hepatocyte proliferation after injury. To address the dual challenges of targeted delivery and phagocytosis evasion, we develop a combined "eat me/don't eat me" strategy. RLTRKRGLK (RLTR) peptide-functionalized exosomes are engineered by inserting DMPE-PEG2000-CRLTRKRGLK into the lipid membrane of exosome derived from bEnd.3 cell. Surface-displayed RLTR mediates exosomal enrichment in LSEC, while CD47 engineering reduces macrophage clearance via "don't eat me" signaling. Then, lentiviral transfection enables stable encapsulation of functional Wnt2 mRNA into Exo (designated Wnt2@Exo). In both acetaminophen (APAP) and dimethylnitrosamine (DMN)-induced murine liver injury models, RLTR-Wnt2@Exo demonstrates LSEC-specific targeting and significant hepatoprotection. This engineered exosome platform provides a therapeutic strategy for DILI.
药物性肝损伤(DILI)涉及多方面的发病机制,需要有效的治疗策略。肝窦内皮细胞(LSEC)分泌的Wnt2可激活Wnt/β-连环蛋白信号通路,以促进损伤后肝细胞的增殖。为应对靶向递送和逃避吞噬这两个双重挑战,我们开发了一种组合的“吃我/别吃我”策略。通过将DMPE-PEG2000-CRLTRKRGLK插入源自bEnd.3细胞的外泌体脂质膜中,构建了RLTRKRGLK(RLTR)肽功能化的外泌体。表面展示的RLTR介导外泌体在LSEC中富集,而CD47工程改造通过“别吃我”信号减少巨噬细胞清除。然后,慢病毒转染可将功能性Wnt2 mRNA稳定封装到外泌体中(命名为Wnt2@Exo)。在对乙酰氨基酚(APAP)和二甲基亚硝胺(DMN)诱导的小鼠肝损伤模型中,RLTR-Wnt2@Exo均表现出对LSEC的特异性靶向作用和显著的肝保护作用。这种工程化的外泌体平台为DILI提供了一种治疗策略。
Cell Rep Med. 2025-4-15
Prostaglandins Leukot Essent Fatty Acids. 2024-3
J Extracell Vesicles. 2020-8-19
Biochem Pharmacol. 2013-7-19
Heliyon. 2023-9-29
Biomaterials. 2017-1-3
Cancer Cell. 2023-12-11
Signal Transduct Target Ther. 2023-3-15
Cell Mol Gastroenterol Hepatol. 2022